Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Baird 2016 Global Healthcare Conference

NOVATO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 23, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting

NOVATO, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 09, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Upcoming Investor Conferences

NOVATO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 08, 2016 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update

NOVATO, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 01, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update

NOVATO, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
July 28, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH)

NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
July 27, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy

NOVATO, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
July 14, 2016 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

Study meets primary endpoint of reduction in urinary GAG excretion and provides evidence of clinical improvement Company to host conference call today at 5pm ET to discuss results NOVATO, Calif.,...
July 13, 2016 16:15 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases

NOVATO, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
June 28, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia

NOVATO, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...